Dan Kisner - Dynavax Technologies Independent Director
| DVAX Stock | USD 11.34 0.09 0.79% |
Director
Dr. Daniel L. Kisner M.D. is an Independent Director of Dynavax Technologies Corporation since July 22 2010. From 2003 to 2010 Dr. Kisner served as a partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies leading its evolution from a startup focused on microfluidic labonchip technology to a publicly traded commercial organization. Prior to Caliper he was the President and Chief Operating Officer of Isis Pharmaceuticals Inc. a biomedical pharmaceutical company. Previously Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition he held a tenured position in the Division of Oncology at the University of Texas San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology since 2010.
| Age | 67 |
| Tenure | 14 years |
| Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0106) %, meaning that it created substantial loss on money invested by shareholders. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 19.9 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Garen Bohlin | Collegium Pharmaceutical | 70 | |
| Edward Owens | Ironwood Pharmaceuticals | 71 | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Sriram Venkataraman | Lantheus Holdings | 44 | |
| Patrick Walsh | ANI Pharmaceuticals | 57 | |
| Stephen Shohet | Amphastar P | 82 | |
| Andrew Dreyfus | Ironwood Pharmaceuticals | 59 | |
| David Anstice | Alkermes Plc | 69 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Lawrence Olanoff | Ironwood Pharmaceuticals | 66 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| John Fallon | Collegium Pharmaceutical | 70 | |
| Terrence Blaschke | Durect | 71 | |
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Gary Pace | Pacira Pharmaceuticals | 70 | |
| Julie McHugh | Lantheus Holdings | 53 | |
| David Burgstahler | Lantheus Holdings | 47 | |
| Jay Shepard | Durect | 56 | |
| Gino Santini | Collegium Pharmaceutical | 61 | |
Management Performance
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arnold Oronsky, Independent Chairman of the Board | ||
| Francis Cano, Independent Director | ||
| Daniel Kisner, Independent Director | ||
| Dennis Carson, Independent Director | ||
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
| Eddie Gray, CEO and Director | ||
| Peggy Phillips, Independent Director | ||
| Nicole Arndt, Sr Relations | ||
| Laura Brege, Director | ||
| David Johnson, Chief Accounting Officer, Vice President | ||
| Andrew Hack, Director | ||
| John Slebir, Senior Counsel | ||
| Jeff Coon, CHRO Administration | ||
| Meg Smith, VP Operations | ||
| Todd Lopeman, Senior Operations | ||
| Stanley Plotkin, Independent Director | ||
| Dan Kisner, Independent Director | ||
| Riccardo Manetti, Business President | ||
| Eric Frings, Site VP | ||
| Natale Ricciardi, Director | ||
| David Novack, Sr. VP of Operations and Quality | ||
| Donn Casale, Chief Officer | ||
| Kelly MacDonald, Senior CFO | ||
| Paul Cox, VP Communications | ||
| Dong Yu, Senior Research | ||
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
| Robert Coffman, Chief Scientific Officer and Sr. VP | ||
| Justin Burgess, Principal Controller | ||
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 995.78 M | ||||
| Shares Outstanding | 130.86 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 17.97 M | ||||
| Price To Earning | 6.95 X |
Pair Trading with Dynavax Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dynavax Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dynavax Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Dynavax Stock
| 0.7 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Dynavax Stock
| 0.58 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.52 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.45 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Dynavax Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dynavax Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dynavax Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dynavax Technologies to buy it.
The correlation of Dynavax Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dynavax Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dynavax Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dynavax Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.05) | Revenue Per Share 1.804 | Quarterly Revenue Growth (0.70) | Return On Assets (0.02) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.